$RCUS

Arcus Biosciences, Inc.

Arcus Biosciences is a late clinical-stage biopharmaceutical company developing medicines for patients with cancer and inflammatory and autoimmune diseases. Its oncology portfolio includes casdatifan, quemliclustat, domvanalimab and zimberelimab, which it evaluates in clinical trials, including Phase 3 studies. Its inflammation portfolio includes five research and preclinical programs targeting MRGPRX2, TNF, CCR6, CD89 and CD40 ligand, with an emphasis on oral small-molecule drugs. Arcus makes money through collaborations and licenses that provide partners development and commercialization rights, in exchange for payments and royalties. It retains commercial rights to casdatifan in most territories and has elected to co-promote domvanalimab and zimberelimab with Gilead in the U.S.; it expects to make the same election for quemliclustat. Arcus relies on third parties to manufacture, package, store and distribute its investigational products. It is headquartered in Hayward, California.

AlphAI earnings readthird quarter 2026 · NOV 4Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline UpdateVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $RCUS in the last 7 days.

No SEC Form 4 filings for $RCUS in the last 30 days.

See all $RCUS insider activity →

RCUS sentiment & insider activity

Recent RCUS coverage spans financial news, earnings and corporate actions.

What's driving RCUS

  • Leerink Partners kept Arcus Biosciences at Outperform, raising its price target to $49 from $46, a 6.5% increase. The target suggests 153.8% upside from the Nov 4 close of $19.31. Recent analyst notes on the company have price targets ranging from $40 to $50.

    tradingview.com · Nov 5, 2026

  • Truist Securities kept its Buy rating on Arcus Biosciences but reduced its price target to $40 from $41, citing a 2.4% decrease. The new target suggests a 107.1% upside from the Nov 4 close of $19.31. Other recent analyst price targets for the company range from $41 to $50.

    tradingview.com · Nov 5, 2026

  • Wedbush kept Arcus Biosciences at Outperform but cut its price target to $45 from $49, an 8.2% reduction. The new target suggests a 133.0% upside from the Nov 4 close of $19.31. Recent analyst price targets for the company range from $41 to $50.

    tradingview.com · Nov 5, 2026

  • Positive trial readouts and clear development milestones suggest near‑term upside.

    SEC EDGAR 8-K · Nov 4, 2026

  • Investors will watch the earnings release for guidance on cash runway and trial milestones; any surprise could move the stock.

    investing.com · Nov 4, 2026

AlphAI scores every news story that mentions RCUS with an AI model for sentiment and relevance, and aggregates insider trades from Arcus Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RCUS

Score
$RCUSMedAI 8/10Earnings

Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update November 4, 2026 • ARC-20 data presented in October demonstrated the extraordinary opportunity for casdatifan to be a backbone treatment across every line of kidney cancer t

$RCUSLowOffering· $269.7M · closed

Arcus Biosciences, Inc. entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, as representatives of…

Arcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 21, 2026, Arcus Biosciences, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters name

Arcus Biosciences, Inc. (RCUS): Results of Operations and Financial Condition

Arcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. Based upon preliminary estimates and information available to Arcus Biosciences, Inc. (the “Company”) as of October 21, 2026, the Company estimates that it had approximately $694.0 million in cash, cash equivalents and mark

Related tickers